Revenue and Profit - Revenue for Q3 2023 was CNY 109,316,534.77, an increase of 3.37% year-over-year, while year-to-date revenue decreased by 2.08% to CNY 311,118,638.38[5] - Net profit attributable to shareholders for Q3 2023 was CNY 21,377,754.66, down 13.28% year-over-year, and year-to-date net profit decreased by 7.23% to CNY 71,412,640.45[5] - Basic earnings per share for Q3 2023 was CNY 0.21, a decrease of 35.33% compared to the same period last year, with year-to-date earnings per share at CNY 0.71, down 30.39%[5] - Total operating revenue for Q3 2023 was CNY 311,118,638.38, a decrease of 2.0% compared to CNY 317,715,861.50 in Q3 2022[19] - Net profit for Q3 2023 was CNY 73,602,344.79, down 5.0% from CNY 77,519,252.60 in Q3 2022[20] - Earnings per share (EPS) for Q3 2023 was CNY 0.71, compared to CNY 1.02 in the same period last year[20] Cash Flow and Financial Position - The company reported a net cash flow from operating activities of CNY 98,344,712.94, an increase of 22.81% year-to-date[5] - Cash inflow from operating activities was CNY 403,263,084.54, an increase of 18.1% from CNY 341,387,358.86 in Q3 2022[22] - The net cash flow from operating activities for Q3 2023 was ¥98,344,712.94, an increase of 22.8% compared to ¥80,079,637.49 in Q3 2022[23] - The total cash outflow from investing activities was ¥1,014,015,008.93, up 31.5% from ¥771,149,119.96 in the same period last year[23] - The net cash flow from investing activities was -¥556,203,244.86, worsening from -¥102,324,633.01 year-over-year[23] - The cash flow from operating activities was impacted by a total cash outflow of ¥304,918,371.60, compared to ¥261,307,721.37 in the previous year[23] Assets and Liabilities - Total assets as of September 30, 2023, were CNY 2,368,395,851.40, a decrease of 0.65% from the end of the previous year[5] - The company's cash and cash equivalents decreased by 47.07% to CNY 588,417,043.52 compared to the beginning of the year[8] - The company's total liabilities decreased to CNY 138,999,277.99 from CNY 180,044,797.30 year-over-year[19] - The total current assets decreased to CNY 1,446,227,017.57 from CNY 1,485,218,174.08, a decline of about 3%[17] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 13,377[11] - The largest shareholder, Wan Shiping, holds 25.01% of the shares, totaling 25,052,934 shares[11] - The company has a significant number of shares held by major shareholders, with 万世平 holding 25,052,934 shares[14] Government Support and Other Income - The company received government subsidies amounting to CNY 408,480.35 during the reporting period, mainly from tax rewards and listing incentives[6] - Other income rose by 118.57% to 13,100,464.28 CNY primarily from government subsidies received[9] - Cash received from tax refunds increased by 194.36% to 6,873,344.86 CNY due to higher tax refund amounts[10] - Cash received from other operating activities rose by 197.34% to 24,345,622.49 CNY, mainly from government subsidies and bank interest[10] Expenses and Financial Performance - Total operating costs increased to CNY 250,384,360.50, up 5.0% from CNY 236,611,808.79 in the previous year[19] - Research and development expenses for the period were CNY 20,237,381.58, up from CNY 18,398,015.50 in the previous year[19] - Financial expenses increased by 2,698.03% to -8,824,150.92 CNY due to increased bank deposit interest income[9] - The company reported a financial income of CNY 8,981,112.92, compared to CNY 148,144.89 in the previous year[19] Strategic Focus and Future Plans - The company plans to maintain its strategic focus on expanding its market presence and developing new technologies[16] - The company has a scheduled release of restricted shares for several major shareholders, with dates ranging from November 30, 2023, to May 30, 2026[14] Audit and Accounting Standards - The company did not undergo an audit for the Q3 2023 report[24] - The company has not adopted the new accounting standards for the current year[24]
东星医疗(301290) - 2023 Q3 - 季度财报